ArticleEuropean journal of pediatrics2025
Does gonadotropin-releasing hormone analogue treatment alter body mass index in boys with central precocious puberty?
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence.Clinics and practice · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Existing data regarding effects of long-acting gonadotropin-releasing hormone analogues (GnRHa) on body mass index (BMI) in boys with idiopathic central precocious puberty (iCPP) are inadequate. Evaluating the effect of GnRHa on BMI in boys with iCPP during and after treatment completion at final height (FH) was aimed. Eighty boys with iCPP who completed GnRHa (leuprolide acetate, 3.75 mg (every 4 weeks)) were enrolled. Auxologic measurements were conducted at the beginning and yearly until treatment completion, then at FH (7.0 ± 1.3 years after treatment completion) in 58. Subgroup analysis were conducted according to pretreatment BMI status (42.5%: normal weight (NW), 30.0% overweight (OW), 27.5% obese (OB)). Mean BMI-SDS (1.3 ± 0.9) remained unchanged until 2nd year (1.5 ± 0.7 SDS, 1.3 ± 0.7 SDS, p = 0.956, p = 0.978) then decreased at FH (0.9 ± 1.5 SDS; p = 0.000). In NWs, BMI-SDS increased during the 1st year (0.5 ± 0.8 SDS to 1.2 ± 0.7; p = 0.031). In OBs, it decreased during the 2nd year (2.3 ± 0.6 to 1.7 ± 0.9; p = 0.000). BMI-SDS at FH returned to pretreatment in NWs, remained the same in OW, and decreased in OBs (p = 0.001). Adult BMI-SDS positively correlated with pretreatment BMI-SDS (r = 0.477, p = 0.001).
conclusionIncrease in BMI-SDS during the first year of GnRHa was only observed in NWs while OW and OBs maintained BMI-SDS. During adulthood, this increase of BMI-SDS in NWs was reversed while OBs exhibited a significant decrease. Lifestyle and diet programs should be implemented to NWs as well as OW and OBs boys with iCPP when initiating GnRHa treatment. WHAT IS KNOWN: • Fat and lean mass increase with a striking sex difference during physiologic puberty. Suppression using GnRHa treatment in boys with CPP is expected to have implications on body composition; however, existing data are insufficient. WHAT IS NEW: • Depending on pretreatment BMI status, GnRHa treatment has varying implications on BMI-SDS in boys with iCPP. NW boys have a higher risk of weight gain; thus, NW boys and their families should be counseled on this risk and management strategies (healthy dietary and physical activity) at the beginning of GnRHa treatment as should OW and OB boys.
Indexed as
Identifiers
41320712What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.